Aziz to Chair Neuroscience Initiative for Ohio Clinical Trials Collaborative

Working Group Will Advance New Treatments for Patients Suffering From Neurological Disorders

2014 BIO International Convention

CLEVELAND--()--The Ohio Clinical Trials Collaborative (OCTC) announces the appointment of Dina Aziz, MSHS, CCRP, as Chair of its Neuroscience Working Group. Aziz is the Director of Research of the Neuroscience Program at The Ohio State University (OSU) Wexner Medical Center.

“The impact of neurological disorders is far-reaching, encompassing over 1,000 disorders of the brain and nervous system, and affecting over one billion individuals worldwide. New technologies and therapies are greatly needed to treat these disorders. I am honored to be given the opportunity to lead this statewide initiative in neuroscience clinical trials for the OCTC,” said Aziz.

The OCTC provides centralized access to Ohio’s premier medical centers for clinical trial development. The pharmaceutical industry faces a challenging and expensive process for conduct of clinical trials. The OCTC streamlines the contracting, budgeting, approval of human subject use and patient recruitment/enrollment processes to move medical discoveries to market faster.

“The OCTC will establish Ohio as one of the most efficient and effective states in which to develop new medicines and treatment strategies. Neurosciences are a broad disease area of growing need where we look to support industry-sponsored clinical trials,” said James Chmiel, MD, MPH, Chief Executive and Director of the OCTC.

About the Ohio Clinical Trials Collaborative

The OCTC is an initiative under Governor John Kasich’s vision of a premier research medical corridor in Ohio that is co-founded by the Clinical and Translational Science Collaborative at Case Western Reserve University, the Center for Clinical and Translational Science at The Ohio State University and the Center for Clinical and Translational Science and Training at the University of Cincinnati. With offices at Case Western Reserve University’s School of Medicine, the OCTC seeks to establish Ohio as one of the most efficient and effective states in which to test new medications and treatment strategies. The OCTC offers economies of scale and unique capacity, leveraging expertise from across the state of Ohio to conduct clinical trials on behalf of industry sponsors. For more information, please go to www.ohioclintrials.org.

About The Ohio State University Wexner Medical Center

The Ohio State University Wexner Medical Center is one of the largest and most diverse academic medical centers in the country, and the only academic medical center in central Ohio. The only Central Ohio hospital listed in “America’s Best Hospitals” ranking by U.S. News & World Report, Ohio State’s Wexner Medical Center includes: a top-30 College of Medicine; five hospitals; a unified physician practice; an extensive network of primary and specialty care practices; more than a dozen research centers and institutes; and 20 core laboratories.

Contacts

Ohio Clinical Trials Collaborative
John Peterson, PhD, Global Business Development Director, 216-368-0180
john.r.peterson@case.edu
or
Case Western Reserve University
Jessica Studeny, 216-368-4692
jes91@case.edu

Contacts

Ohio Clinical Trials Collaborative
John Peterson, PhD, Global Business Development Director, 216-368-0180
john.r.peterson@case.edu
or
Case Western Reserve University
Jessica Studeny, 216-368-4692
jes91@case.edu